Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci Academic Article uri icon

Overview

MeSH Major

  • Cancer Vaccines
  • Hemocyanin
  • Immunoglobulin M
  • Lung Neoplasms
  • Sialic Acids
  • Small Cell Lung Carcinoma

abstract

  • Vaccination with NP-polySA-KLH resulted in consistent high-titer antibody responses, with the 10 μg dose significantly more immunogenic than the 3 μg dose. This study establishes the lowest optimally immunogenic dose of NP-polysialic acid in this NP-polysialic acid-KLH conjugate vaccine to be at least 10 μg, and it establishes the vaccine's safety. We plan to incorporate NP-polySA into a polyvalent vaccine against SCLC with four glycolipid antigens also widely expressed in SCLC-GD2, GD3, fucosylated GM1, and globo H.

publication date

  • January 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3732393

Digital Object Identifier (DOI)

  • 10.1007/s00262-011-1083-6

PubMed ID

  • 21811785

Additional Document Info

start page

  • 9

end page

  • 18

volume

  • 61

number

  • 1